Blood pressure control in kidney transplantation: Therapeutic implications

Journal of Human Hypertension

Volumn 18, Issue 12, 2004, Pages 871-877

  Premasathian, N C ^a   Muehrer, R ^a   Brazy, P C ^a   Pirsch, J D ^a   Becker, B N ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Angiotensin receptor blockers; Angiotensin converting enzyme inhibition; Blood pressure; Calcium channel antagonists; Kidney transplantation

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BASILIXIMAB; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CAUCASIAN; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG CLASSIFICATION; DRUG EFFICACY; FEMALE; GRAFT SURVIVAL; HUMAN; HYPERTENSION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PROTEINURIA; RETROSPECTIVE STUDY; RISK FACTOR; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; FEMALE; GRAFT REJECTION; HUMANS; HYPERTENSION; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 10044259549     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001767     Document Type: Article

References (15)

1. Hariharan S et al. Improved graft survival after renal transplantation in the United States 1988 to 1996. N Engl J Med 2000; 342: 605-612.
2. First MR, Neylan JF, Rocher LL, Tejani A. Hypertension after renal transplantation. J Am Soc Nephrol 1994; 4: S30-S36.
3. van der Schaaf MR et al. Hypertension after renal transplantationCalcium channel or converting enzyme blockade? Hypertension 1995; 25: 77-81.
4. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998; 53: 217-222.
5. Mange KC, Cizman B, Joffe M, Feldman HI. Arterial hypertension renal allograft survival. JAMA 2000; 283: 633-638.
6. Cosio FG et al. Elevated blood pressure predicts the risk of acute rejection in renal allograft recipients. Kidney Int 2001; 59: 1158-1164.
7. Raman GV et al. Modifying effects of amlodipine on cyclosporin. A-induced changes in renal function in patients with psoriasis. J Hypertens Suppl 1998; 16: S39-S41.
8. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462.
9. Fleming JT, Parekh N, Steinhausen M. Calcium antagonists preferentially dilate preglomerular vessels of hydronephrotic kidney. Am J Physiol 1987; 253: F1157-63.
10. English J, Evan A, Houghton DC, Bennett WM. Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation 1987; 44:135-141.
11. Ruggenenti P et al. Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney Int 1993; 43: 706-711.
12. Becker BN, Jacobson LJ, Hullett DA. An antigen-independent important hormone:intrarenal angiotensin II (AII) as a key to understanding chronic allograft nephropathy. Graft 2002; 5: 199-204.
13. Stigant CE, Cohen J, Vivera M, Zaltzman JS. ACE inhibitors angiotensin II antagonists in renal transplantation: an analysis of safety efficacy. Am J Kidney Dis 2000; 35: 58-63.
14. Midtvedt K, Hartmann A. Hypertension after kidney transplantation: are treatment guidelines emerging? Nephrol Dial Transplant 2002; 17: 1166-1169.
15. Dudley CR. Treatment of posttransplant hypertension: ACE is trumped? Transplantation 2001; 72: 1728-1729.